SHS_492246 VALE CMGL 14050

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)

This registry is specific to surgeons and is intended to measure the effect of myPlan Lung Cancer test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.

Inclusion Criteria:
•Diagnosis of early stage non-small cell lung adenocarcinoma
•Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
•Resection of tumor within previous 2 months of enrollment
•ECOG performance of 0-2
•A minimum life expectancy of six months

Exclusion Criteria:
•Pre-operative radiation or chemotherapy for NSCLC
•Post-operative radiation or chemotherapy for NSCLC
•Enrollment in a separate clinical trial restricting treatment options
•Unable to provide informed consent
N/A
NCT02121925
Cancer, All Other
Lung
Eric Vallieres, M.D.
Myriad Genetic Laboratories, Inc.
Andrew Smith
  • Swedish Medical Center